Results 41 to 50 of about 356,021 (162)

Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy. [PDF]

Clin J Am Soc Nephrol
Key Points Systemic glucocorticoids could reduce levels of total IgA and galactose-deficient IgA1 (Gd-IgA1) in IgA nephropathy patients, but the effect diminished after treatment discontinuation.
Zan J, Li J, Wong MG, Kim D, Shi S, Monaghan H, Perkovic V, Lv J, Zhang H, TESTING study biomarker group.   +9 more
europepmc   +4 more sources

A Case of IgA Nephropathy in a Patient With Sarcoidosis: Confirmation of Glomerular Galactose-Deficient IgA1 Deposition. [PDF]

Case Rep Nephrol
A 63‐year‐old Japanese housewife was admitted to our hospital because of hematuria and proteinuria lasting for 3 months. At the age of 59 years, she was diagnosed with neurosarcoidosis at another hospital, and she received oral glucocorticoid therapy for 1 year.
Shimizu Y, Ito D, Arakawa M, Shiozaki Y, Suzuki Y, Ito S, Ohashi N, Fujigaki Y, Shimizu A, Yasuda H, Misaki T.   +10 more
europepmc   +4 more sources

Glomerular galactose‐deficient IgA1 detected in donor‐derived and recurrent IgA nephropathy

Transplant International, 2021
Galactose deficient IgA1 (Gd-IgA1) plays an important role in the pathogenesis of IgA nephropathy (IgAN)1 . Immunofluorescence (IF) staining of KM55, a Gd-IgA1 specific monoclonal antibody, becomes an easy and reliable tool to detect Gd-IgA1 deposited in glomerular mesangium of IgAN.
Su, Xuesong, Kim, Youngki, Riad, Samy, Spong, Richard, Bu, Lihong   +4 more
openaire   +2 more sources

Glomerular staining intensity of IgA and galactose-deficient IgA1.

, 2023
Double staining with anti-IgA polyclonal antibody and Gd-IgA1 (KM55) monoclonal antibody was performed on biopsy specimens. Representative images of glomerular IgA and Gd-IgA1 (KM55) in patients with 0, 1+, 2+, and 3+ staining intensity.
Seigo Ito (1353945), Yusuke Suzuki (525707), Ryota Nomura (630559), Daiki Matsuoka (13777279), Kazuhiko Nakano (630560), Shuhei Naka (13777276), Ryosuke Aoki (14709763), Michiyo Matsumoto-Nakano (630562), Hitoshi Suzuki (16714), Yasuyuki Nagasawa (515930), Taro Misaki (168264), Mingfeng Lee (14709760)   +11 more
core   +1 more source

GalNAc-T14 may Contribute to Production of Galactose-Deficient Immunoglobulin A1, the Main Autoantigen in IgA Nephropathy

Kidney International Reports, 2023
Introduction: Immunoglobulin A1 (IgA1) with galactose-deficient O-glycans (Gd-IgA1) play a key role in the pathogenesis of IgA nephropathy (IgAN). Mucosal-tissue infections increase IL-6 production and, in patients with IgAN, are often associated with ...
Jana Jemelkova, Milada Stuchlova Horynova, Petr Kosztyu, Katerina Zachova, Josef Zadrazil, Dana Galuszkova, Kazuo Takahashi, Jan Novak, Milan Raska   +8 more
doaj   +1 more source

Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. [PDF]

PLoS One, 2018
Galactose-deficient IgA1 (Gd-IgA1) is a critical pathogenic factor for IgA nephropathy (IgAN), but its value as a disease-specific biomarker remains controversial. We aimed to clarify the clinical significance of Gd-IgA1 in patients with IgAN.We retrospectively reviewed 111 patients who were diagnosed with IgAN based on the findings of renal biopsies ...
Wada Y, Matsumoto K, Suzuki T, Saito T, Kanazawa N, Tachibana S, Iseri K, Sugiyama M, Iyoda M, Shibata T.   +9 more
europepmc   +5 more sources

Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy [PDF]

Journal of the American Society of Nephrology, 2016
Autoantibodies against galactose-deficient IgA1 drive formation of pathogenic immune complexes in IgA nephropathy. IgG autoantibodies against galactose-deficient IgA1 in patients with IgA nephropathy have a specific amino-acid sequence, Y1CS3, in the complementarity-determining region 3 of the heavy chain variable region compared with a Y1CA3 sequence ...
Zhi Qiang, Huang, Milan, Raska, Tyler J, Stewart, Colin, Reily, R Glenn, King, David K, Crossman, Michael R, Crowley, Audra, Hargett, Zhixin, Zhang, Hitoshi, Suzuki, Stacy, Hall, Robert J, Wyatt, Bruce A, Julian, Matthew B, Renfrow, Ali G, Gharavi, Jan, Novak   +15 more
openaire   +2 more sources

Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.

PLoS ONE, 2016
ObjectiveGalactose-deficient IgA1 was evaluated in patients with IgA nephropathy(IgAN) and controls in order to determine the predictive value of galactose-deficient IgA1 in cases of IgA nephropathy.MethodsPubMed, EMBASE, Cochrane central register of ...
Qiang Sun, Zhenhai Zhang, Hong Zhang, Xiaorong Liu   +3 more
doaj   +1 more source

261 Characterization of Glycosylation Patterns of Single IgA Molecules Using Single-Molecule Fluorescence Microscopy

Journal of Clinical and Translational Science, 2023
OBJECTIVES/GOALS: IgA1 nephropathy, which can lead to kidney failure, is caused by complexes formed between aberrant galactose-deficient IgA1 and antibodies directed against it.
Joseph Rubin, Milan Stojanovic, Ali Gharavi, Henry Hess   +3 more
doaj   +1 more source

Mass spectrometry-based approach for development of biomarkers in IgA nephropathy: a pilot trial

Fujita Medical Journal, 2018
IgA1 with galactose (Gal)-deficient hinge-region (HR) O-glycans (Gd-IgA1) plays a key role in IgA nephropathy (IgAN), and the serum level of Gd-IgA1 is elevated in the majority of IgAN patients.
Ayako Kondo, Kazuo Takahashi, Hisateru Yamaguchi, Yuri Yoshida, Tomohiro Mizuno, Kazuki Nakajima, Hiroki Hayashi, Shigehisa Koide, Daijo Inaguma, Midori Hasegawa, Yoshiyuki Hiki, Yukio Yuzawa   +11 more
doaj   +1 more source